JP2006514614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514614A5 JP2006514614A5 JP2004546183A JP2004546183A JP2006514614A5 JP 2006514614 A5 JP2006514614 A5 JP 2006514614A5 JP 2004546183 A JP2004546183 A JP 2004546183A JP 2004546183 A JP2004546183 A JP 2004546183A JP 2006514614 A5 JP2006514614 A5 JP 2006514614A5
- Authority
- JP
- Japan
- Prior art keywords
- activity
- assay
- enzyme
- hsd1
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 238000004166 bioassay Methods 0.000 description 25
- 230000003228 microsomal Effects 0.000 description 23
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 20
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 20
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229960004544 cortisone Drugs 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 210000004185 Liver Anatomy 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 229960000890 hydrocortisone Drugs 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 210000001853 Microsomes, Liver Anatomy 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 125000002009 alkene group Chemical group 0.000 description 8
- 102000004965 antibodies Human genes 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000001952 enzyme assay Methods 0.000 description 8
- -1 oxygen hydrocarbon Chemical class 0.000 description 8
- 210000001589 Microsomes Anatomy 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18β-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- 210000003734 Kidney Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 230000036715 Apparent Km Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OBZHEBDUNPOCJG-WBXJDKIVSA-N Carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-WBXJDKIVSA-N 0.000 description 3
- 229940073144 Glycyrrhetinic acid Drugs 0.000 description 3
- 206010022489 Insulin resistance Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 229960000530 carbenoxolone Drugs 0.000 description 3
- 230000024881 catalytic activity Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 102000004277 11-beta-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-Hydroxysteroid Dehydrogenases Proteins 0.000 description 1
- OWSNXLPHOKXBBX-UHFFFAOYSA-N 2-N-phenylbenzene-1,2,4-triamine Chemical compound NC1=CC=C(N)C(NC=2C=CC=CC=2)=C1 OWSNXLPHOKXBBX-UHFFFAOYSA-N 0.000 description 1
- AMYCGTZQZUYICB-UHFFFAOYSA-N 2-[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]-N,N-diethylacetamide Chemical compound C1=C2SC(CC(=O)N(CC)CC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C AMYCGTZQZUYICB-UHFFFAOYSA-N 0.000 description 1
- LMIJHHNOLSGCFI-UHFFFAOYSA-N 2-[[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]-N,N-diethylacetamide Chemical compound C1=C2SC(SCC(=O)N(CC)CC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C LMIJHHNOLSGCFI-UHFFFAOYSA-N 0.000 description 1
- SDRNNYJXRMLMIQ-UHFFFAOYSA-N 3-chloro-N,2-dimethyl-N-(3-methyl-2-oxo-1,3-benzothiazol-6-yl)benzenesulfonamide Chemical compound C=1C=C2N(C)C(=O)SC2=CC=1N(C)S(=O)(=O)C1=CC=CC(Cl)=C1C SDRNNYJXRMLMIQ-UHFFFAOYSA-N 0.000 description 1
- WVLMEXKPDOOWDU-UHFFFAOYSA-N 3-chloro-N-(1,2-dimethylbenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound C=1C=C2N(C)C(C)=NC2=CC=1NS(=O)(=O)C1=CC=CC(Cl)=C1C WVLMEXKPDOOWDU-UHFFFAOYSA-N 0.000 description 1
- GASJDYJSWXNTJU-UHFFFAOYSA-N 3-chloro-N-(2,3-dimethylbenzimidazol-5-yl)-2-methylbenzenesulfonamide Chemical compound C1=C2N(C)C(C)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C GASJDYJSWXNTJU-UHFFFAOYSA-N 0.000 description 1
- ZYVQAIDSWNFREL-UHFFFAOYSA-N 3-chloro-N-(2,5-dimethyl-1,3-benzothiazol-4-yl)-2-methylbenzenesulfonamide Chemical compound CC1=CC=C2SC(C)=NC2=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C ZYVQAIDSWNFREL-UHFFFAOYSA-N 0.000 description 1
- LNQWPSSYYDUERX-UHFFFAOYSA-N 3-chloro-N-(2,6-dimethyl-1,3-benzothiazol-7-yl)-2-methylbenzenesulfonamide Chemical compound C=12SC(C)=NC2=CC=C(C)C=1NS(=O)(=O)C1=CC=CC(Cl)=C1C LNQWPSSYYDUERX-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- 101700010451 CELB Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 101700041462 GUX2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007565 Gingivitis Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 229940045189 Glucose-6-Phosphate Drugs 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 206010026673 Malignant pleural effusion Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- AEUCZQDDOWUIAW-UHFFFAOYSA-N N-(2-methyl-1-phenylbenzimidazol-5-yl)acetamide Chemical compound CC1=NC2=CC(NC(=O)C)=CC=C2N1C1=CC=CC=C1 AEUCZQDDOWUIAW-UHFFFAOYSA-N 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 231100000618 Neurotoxin Toxicity 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 Rhodamine B Drugs 0.000 description 1
- 101700061430 SAT19 Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 101700081234 TTR Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001837 anti-cortisol Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 101700046922 cex Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 108091007687 cortisol binding proteins Proteins 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BJOVOWDUSPGFTN-UHFFFAOYSA-N ethyl 2-[[6-[(3-chloro-2-methylphenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]acetate Chemical compound C1=C2SC(SCC(=O)OCC)=NC2=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1C BJOVOWDUSPGFTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000037327 stress response Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Description
(発明の分野)
本発明は、ある化合物に関連する。特に、本発明は、11β−ヒドロキシステロイドデヒドロゲナーゼ(11β−HSD)を阻害し得る化合物を提供する。
(Field of Invention)
The present invention relates to certain compounds. In particular, the present invention provides compounds that can inhibit 11β-hydroxysteroid dehydrogenase ( 11β- HSD).
11β−HSD1型は、特定の組織が、コルチゾンをコルチゾールに変換して、局所的な糖質コルチコイド活性を増加させ、適合応答を増強することを可能にし、糖質コルチコイドの活性の失敗を生じ得る2型活性を相殺する[10]。ストレス応答の増強は、脳において特に重要であり、高レベルの11β−HSD1型が、海馬周辺で見られ、さらに、この酵素の役割を解明する。11β−HSD1型はまた、肝細胞成熟において重要な役割を果たすようである[8]。11β−HSD1型酵素の別の新生の役割は、多くの非ステロイド性カルボニル化合物の解毒プロセスにあり、多くの毒性化合物のカルボニル基の還元は、溶解性を高め、従って、その外分泌を増加させるための一般的な方法である。11β−HSD1型酵素は、最近、肺組織において活性であることが示されている[11]。1型の活性は、生後までは見られず、従って、妊娠の間に喫煙する母親がその子供に対して、子供がこの化合物を代謝的に解毒し得るようになる前に、タバコの有害な作用を与える。 11β-HSD type 1 may allow certain tissues to convert cortisone to cortisol, increase local glucocorticoid activity, enhance the fit response, and cause failure of glucocorticoid activity. Offsets type 2 activity [10]. Enhancement of the stress response is particularly important in the brain, and high levels of 11β-HSD type 1 are found around the hippocampus and further elucidate the role of this enzyme. 11β-HSD type 1 also appears to play an important role in hepatocyte maturation [8]. Another emerging role for the 11β-HSD type 1 enzyme is in the detoxification process of many non-steroidal carbonyl compounds, since the reduction of the carbonyl group of many toxic compounds increases solubility and thus increases its exocrine secretion. Is a general method. The 11β-HSD type 1 enzyme has recently been shown to be active in lung tissue [11]. Type 1 activity is not seen until after birth, and therefore the harmful cigarettes of a mother who smokes during pregnancy before her child can metabolically detoxify this compound. Gives action.
R1およびR2のうちの1つは、以下の式:
One of R 1 and R 2 has the following formula:
代替的な観点から、本発明は、肝臓インシュリン抵抗性、脂肪組織のインシュリン抵抗性、筋肉のインシュリン抵抗性、糖質コルチコイドにより増強された神経毒に起因するニューロンの喪失または機能不全ならびに上記の状態の任意の組合せからなる群から選択される状態に罹患しているヒトもしくは動物被験体の処置方法を提供し、この方法は、上記患者に本発明に記載される化合物の薬学的に活性な量を含む医薬を投与する工程を包含する。 From an alternative perspective, the present invention relates to liver insulin resistance, adipose tissue insulin resistance, muscle insulin resistance, neuronal loss or dysfunction caused by glucocorticoid-enhanced neurotoxins, as well as the conditions described above. A method for the treatment of a human or animal subject suffering from a condition selected from the group consisting of any combination of the above, wherein the method comprises administering to the patient a pharmaceutically active amount of a compound described in the present invention. Administering a medicament comprising:
好ましくは、R11、R12、R13、R14およびR15の各々は、独立して、H、ハロゲン、アルキル(例えば、C1〜C6アルキル、フェニル、O−アルキル、O−フェニル、ニトリル、ハロアルキル(例えば、CF3、CCl3およびCBr 3)、カルボキシアルキル、−CO2H、CO2アルキルおよびNH−アセチル基から選択される。 Preferably, each of R 11 , R 12 , R 13 , R 14 and R 15 is independently H, halogen, alkyl (eg, C 1 -C 6 alkyl, phenyl, O-alkyl, O-phenyl, Selected from nitrile, haloalkyl (eg CF 3 , CCl 3 and CB r 3 ), carboxyalkyl, —CO 2 H, CO 2 alkyl and NH-acetyl groups.
(置換基)
本発明の化合物は、本明細書中に示される環系以外の置換基を有し得る。さらに、本明細書中の環系は、一般式として与えられ、このように解釈されるべきである。所定の環メンバー上に具体的に示される置換基が存在しない場合、環メンバーは、任意の置換基で置換されていてもよく、Hはほんの一例である。環系は、1以上の程度の不飽和を含み得、例えば、いくつかの局面において、環系の1つ以上の環は芳香族である。環系は、炭素環式であり得るか、または、1つ以上のヘテロ原子を含み得る。
(Substituent)
The compounds of the present invention may have substituents other than the ring systems shown herein. Furthermore, the ring systems herein are given as general formulas and should be interpreted in this way. In the absence of a specifically indicated substituent on a given ring member, the ring member may be substituted with any substituent and H is only one example. A ring system can contain one or more degrees of unsaturation, for example, in some aspects, one or more rings of the ring system are aromatic. The ring system can be carbocyclic or can contain one or more heteroatoms.
代表的なヒドロカルビル基は、炭化水素基である。ここで、用語「炭化水素」とは、基が直鎖状、分枝もしくは環状であり得るアルキル基、アルケニル基、アルキニル基、またはアリール基のうちのいずれか1つを意味する。用語「炭化水素」はまた、必要に応じて置換されているこれらの基を含む。炭化水素が置換基を有する分枝構造である場合、置換は、炭化水素骨格上または分枝鎖上のいずれかであり得る;あるいは、置換は、炭化水素骨格および分枝鎖上にあり得る。 A typical hydrocarbyl group is a hydrocarbon group. Here, the term “hydrocarbon” means any one of an alkyl group, an alkenyl group, an alkynyl group, or an aryl group, which may be linear, branched or cyclic . The term “hydrocarbon” also includes those groups that are optionally substituted. Where the hydrocarbon is a branched structure with substituents, the substitution can be either on the hydrocarbon backbone or on the branched chain; alternatively, the substitution can be on the hydrocarbon backbone and the branched chain.
本発明のいくつかの局面において、1つ以上のヒドロカルビル基は、独立して、アルケン基から選択される。代表的なアルケン基としては、C1〜C10アルケン基、C 1 −C 6 アルケン基、C1−C3アルケン基(例えば、C1、C2、C3、C4、C5、C6またはC7アルケン基)を含む。好ましい局面において、アルケン基は、1、2または3のC=C結合を含む。好ましい局面において、アルケン基は、1つのC=C結合を含む。いくつかの好ましい局面において、少なくとも1つのC=C結合または1つのみのC=C結合は、アルケン鎖のC末端にあり、すなわち、結合は、環系に対して鎖の遠位端にある。 In some aspects of the invention, the one or more hydrocarbyl groups are independently selected from alkene groups. Typical alkene groups include C 1 -C 10 alkene groups, C 1 -C 6 alkene groups, C 1 -C 3 alkene groups (eg, C 1 , C 2 , C 3 , C 4 , C 5 , C 5 6 or a C 7 alkene group). In preferred aspects, the alkene group contains 1, 2 or 3 C═C bonds. In a preferred aspect, the alkene group contains one C═C bond. In some preferred aspects, at least one C═C bond or only one C═C bond is at the C-terminus of the alkene chain, ie, the bond is at the distal end of the chain relative to the ring system. .
ここで、用語「酸素炭化水素」とは、基が直鎖、分枝鎖もしくは環状であり得るアルコキシ基、オキシアルケニル基、オキシアルキニル基、またはオキシアリール基のいずれか1つを意味する。用語「酸素炭化水素」はまた、必要に応じて置換されているこれらの基を含む。酸素炭化水素が、置換基を有する分枝構造である場合、置換は、炭化水素骨格上または分枝鎖上のいずれかであり得る;あるいは、置換は、炭化水素骨格上および分枝鎖上であり得る。 Here, the term “oxygen hydrocarbon” means any one of an alkoxy group, an oxyalkenyl group, an oxyalkynyl group, or an oxyaryl group whose group may be linear, branched or cyclic . The term “oxygen hydrocarbon” also includes those groups that are optionally substituted. When the oxygen hydrocarbon is a branched structure with substituents, the substitution can be either on the hydrocarbon backbone or on the branched chain; alternatively, the substitution is on the hydrocarbon backbone and on the branched chain possible.
代表的には、オキシヒドロカルビル基は、式C1〜6 O(例えば、C1〜3O)のものである。 Typically, the oxyhydrocarbyl group is of the formula C 1-6 O (eg C 1-3 O).
レポーター分子の例としては、(β−ガラクトシダーゼ、インベルターゼ、緑色蛍光タンパク質、ルシフェラーゼ、クロラムフェニコール、アセチルトランスフェラーゼ、(−グルクロニダーゼ、エキソ−グルカナーゼおよびグルコアミラーゼが挙げられるが、これらに限定されない。あるいは、放射標識されるかまたは蛍光タグ標識されたヌクレオチドは、新生転写物に取り込まれ得、これは、次いで、オリゴヌクレオチドプローブに結合する場合に、同定される。 Examples of reporter molecules include (but are not limited to (β-galactosidase, invertase, green fluorescent protein, luciferase, chloramphenicol, acetyltransferase, (-glucuronidase, exo-glucanase and glucoamylase). Radiolabeled or fluorescent tag labeled nucleotides can be incorporated into nascent transcripts, which are then identified when bound to oligonucleotide probes.
異なる送達系に依存した異なる組成物/処方物の要求が存在し得る。例として、本発明の薬学的組成物は、処方されて、ミニポンプを用いてかまたは粘膜経路 によって(例えば、吸入のための経鼻スプレーもしくはエーロゾルまたは摂取可能溶液として)送達され得るか、または組成物が送達(例えば、静脈内経路によるか、筋内経路によるか、または皮下経路による)のために注射可能な形態で処方される非経口送達される。あるいは、処方物は両方の経路によって送達されるように設計され得る。 There may be different composition / formulation requirements dependent on different delivery systems. By way of example, a pharmaceutical composition of the invention can be formulated and delivered using a minipump or by a mucosal route (eg, as a nasal spray or aerosol for inhalation or an ingestible solution) or a composition The article is delivered parenterally formulated in an injectable form for delivery (eg, by intravenous, intramuscular or subcutaneous route). Alternatively, the formulation can be designed to be delivered by both routes.
さらに、または代替的に、本発明の化合物は、生物学的応答の修飾因子と組合わせて使用され得る。 Et al., Or alternatively of, the compounds of the present invention may be used in combination with modulators of biological response.
さらなる例として、本発明の薬剤は、一日あたり1〜4回、好ましくは1日あたり1回または2回のレジメンに従って投与され得る。任意の特定の患者に対する特定の用量レベルおよび投薬頻度は、変動し得、そして種々の因子(使用される特定の化合物の活性、この化合物の代謝安定性および作用の長さ、年齢、体重、全身の健康、性別、食事、投与形式および時間、排出速度、薬物の組み合わせ、特定の状態の重篤度、および宿主が受ける治療を含む)に依存する。 As a further example, the agents of the present invention may be administered according to a regimen of 1 to 4 times per day, preferably once or twice per day. The particular dose level and dosing frequency for any particular patient can vary, and various factors (activity of the particular compound used, metabolic stability and length of action of this compound, age, weight, systemic Health, sex, diet, mode of administration and time, elimination rate, combination of drugs, severity of specific condition, and treatment received by the host ).
従って、薬学的投与に関して、本発明の化合物は、従来の薬学的処方技術ならびに薬学的キャリア、アジュバント、賦形剤、希釈剤などを用いて任意の適切な様式で、通常非経口投与のために、処方され得る。おおよその有効用量の割合は、1〜1000mg/日、例えば、10〜900mg/日またはさらに100〜800mg/日の範囲であり得、問題の化合物の個々の活性に依存し、そしてこれは、平均体重(70Kg)の患者に対してである。好ましくそしてより活性である化合物に関する、より有用な投薬量の割合は、200〜800mg/日、より好ましくは200〜500mg/日、最も好ましくは200〜250mg/日の範囲である。これらは、単一投薬レジメンで提供され得、分割された投薬レジメンおよび/または複数の投薬レジメンが、数日間にわたって続く。経口投与に関して、これらは、単一用量あたり100〜500mgの化合物を含む錠剤、カプセル、溶液または懸濁液で処方され得る。あるいは、および好ましくは、この化合物は、適切な非経口的に投与可能なキャリア中に、非経口投与のために処方され、そして200〜800mg、好ましくは200〜500mg、より好ましくは200〜250mgの範囲の単一日投薬量の割合を提供する。しかし、このような有効日用量は、活性成分の本来の活性、患者の体重に依存して変動し、このような変動は、当該分野および医師の判断の範囲内である。 Thus, for pharmaceutical administration, the compounds of the present invention can be prepared for conventional parenteral administration, in any suitable manner using conventional pharmaceutical formulation techniques as well as pharmaceutical carriers, adjuvants, excipients, diluents, and the like. Can be prescribed. The approximate effective dose rate can range from 1-1000 mg / day, such as 10-900 mg / day or even 100-800 mg / day, depending on the individual activity of the compound in question, and this is average For patients with body weight (70 kg). More useful dosage rates for compounds that are preferred and more active range from 200 to 800 mg / day, more preferably from 200 to 500 mg / day, most preferably from 200 to 250 mg / day. These can be provided in a single dosing regimen, with a divided dosing regimen and / or multiple dosing regimes lasting for several days. For oral administration, they can be formulated in tablets, capsules, solutions or suspensions containing 100-500 mg of compound per single dose. Alternatively and preferably, the compound is formulated for parenteral administration in a suitable parenterally administrable carrier and is 200-800 mg, preferably 200-500 mg, more preferably 200-250 mg. Provides a range of single daily dosages. However, such effective daily doses will vary depending on the original activity of the active ingredient, the patient's weight, and such variations are within the judgment of the art and physician.
例えば、本発明の化合物または組成物は、WO−A−99/52890に列挙される障害の処置において有用であり得る(すなわち):
さらに(あるいは)本発明の化合物または組成物は、WO−A−98/05635に列挙される障害の処置において有用であり得る。参照を容易にするために、そのリストの一部をここに挙げる:糖尿病(II型糖尿病を含む)、肥満、癌、炎症または炎症性疾患、皮膚科障害、熱、心血管効果、出血、凝固および急性期反応、悪液質、拒食症、急性感染、HIV感染、ショック状態、宿主対移植片反応、自己免疫疾患、再還流傷害、髄膜炎、片頭痛、およびアスピリン依存性抗血栓症;腫瘍増殖、侵入および伝播、新脈管形成、転移、悪性、腹水および悪性胸水;脳虚血、虚血性心疾患、変形性関節症、慢性関節リウマチ、骨粗しょう症、喘息、多発性硬化症、神経変性、アルツハイマー病、アテローム性動脈硬化症、発作、血管炎、クローン病および潰瘍性大腸炎;歯周炎、歯肉炎;乾癬、アトピー性皮膚炎、慢性潰瘍、表皮水疱症;角膜潰瘍、網膜症および外科創傷治癒;鼻炎、アレルギー性結膜炎、湿疹、アナフィラキシー;再狭窄、うっ血性心不全、子宮内膜症、アテローム性動脈硬化症または内膜硬化症。
For example, the compounds or compositions of the invention may be useful in the treatment of disorders listed in WO-A-99 / 52890 (ie):
Additionally (or) the compounds or compositions of the invention may be useful in the treatment of disorders listed in WO-A-98 / 05635. For ease of reference, some of that list are listed here: diabetes (including type II diabetes), obesity, cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, bleeding, coagulation And acute phase reaction, cachexia, anorexia, acute infection, HIV infection, shock state, host versus graft reaction, autoimmune disease, reperfusion injury, meningitis, migraine, and aspirin-dependent antithrombosis; Tumor growth, invasion and spread, angiogenesis, metastasis, malignant, ascites and malignant pleural effusion; cerebral ischemia, ischemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, Neurodegeneration, Alzheimer's disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcer, epidermolysis bullosa; corneal ulcer, retina And surgical wound healing ; Rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or intimal sclerosis.
(ラット肝臓およびラット腎臓のμlあたりのタンパク質量)
ラット肝臓およびラット腎臓におけるタンパク質量を決定する必要があった。実験をBradford法に従って行なった[14]。以下の方法を用いた:第1に、BSA(タンパク質)溶液を調製した(1mg/ml)。10〜100μgのタンパク質を含むタンパク質溶液を、チューブ内にピペッティングし、蒸留水を用いて容量を調節した。次いで、5mlのタンパク質試薬をチューブに添加し、激しく混合した。吸光度を、試薬ブランクに対して、3mlのキュベットにて、595nmにて15分後および1時間前に測定した。タンパク質の重量を、対応する吸光度に対してプロットし、ラット肝臓およびラット腎臓の細胞質におけるタンパク質濃度を決定するために使用される標準曲線を得た。
(Amount of protein per μl of rat liver and rat kidney)
It was necessary to determine the amount of protein in rat liver and rat kidney. The experiment was performed according to the Bradford method [14]. The following method was used: First, a BSA (protein) solution was prepared (1 mg / ml). A protein solution containing 10 to 100 μg of protein was pipetted into a tube, and the volume was adjusted with distilled water. 5 ml of protein reagent was then added to the tube and mixed vigorously. Absorbance was measured against a reagent blank in a 3 ml cuvette 15 minutes and 1 hour before at 595 nm. The weight of the protein was plotted against the corresponding absorbance to obtain a standard curve used to determine the protein concentration in the cytoplasm of rat liver and rat kidney.
(アッセイ手順−11β−HSDインヒビター)
これらのアッセイにおいて、還元型(1型)および酸化型(2型)の方向の両方で異なるインヒビターの11β−HSD活性に対する影響を評価した。還元型方向において、Eは、基質であり、Fは生成物であり、酸化型の場合には、逆である。ここで記載される方法は、酸化型の方向についてのものである。
(Assay Procedure-11 β-HSD Inhibitor)
In these assays, the effect of different inhibitors on 11β-HSD activity in both reduced (type 1) and oxidized (type 2) directions was evaluated. In the reduced direction, E is the substrate, F is the product, and vice versa for the oxidized form. The method described here is for the direction of the oxidation type.
基質溶液は、PBS−スクロース中の50,000cpm/mlの3H−Fおよび0.5μMのFを含んだ。1mlの基質溶液を各チューブに添加し、インヒビターをまた、「コントロール」および「ブランク」のチューブを除いて、10μMの濃度にて、各チューブに添加した。150μLを、ブランクを除く全てのチューブに添加し、これが、同時に形成された3H−Fの量について補正を行なった。チューブを機械的に振盪する水浴中、37℃にて60分間インキュベートした。腎臓、肝臓のホモジネートの量および用いたインキュベーション時間を、酵素依存性アッセイおよび時間依存性アッセイから得たものであった。インキュベーションの後、5000cpm/50μLの14C−Eおよび50μg/50μLの未標識Eを含有する50μLの回収物を添加して、次の工程において生じるロスを補正した(TLCプレート上のスポットを可視化するため)。次いで、水性混合物を、4mlのエーテル(2×30秒サイクル、激しい混合)で抽出した。水相を凍結した後、エーテル(上側)層を、小さなチューブにデカントし、45℃にて、完全に乾燥するまで蒸発させた。次いで、残留物を、6滴のエーテルに再溶解させ、TLCプレートに移した。TLCプレートをクロロホルム:メタノール(9:1 v/v)溶媒系で展開させ、溶媒の先端が約18cm移動するまで、約90分間TLCプレートを展開させた。生成物Eの位置を、UV光下で可視化し、TLCプレートから切り出し、シンチレーションバイアルに入れた。放射活性を0.5mlメタノールを用いて5分間にわたって溶離した。0.5mlのPBS−スクロースおよび10mlのEcoscintを次いで添加し、激しく混合し、その後、シンチレーションカウンター内でカウントした。サンプルをカウントする前に、2つの全活性バイアルを調製した。これらは、0.5mlの基質溶液、50μLの回収物、0.5mlのメタノールおよび10mlのEcscintを含んだ。これらの2つの全活性バイアルが、最初に添加された14C−Eおよび3H−Fの量を決定して、計算を行なうために必要とされた。 The substrate solution contained 50,000 cpm / ml 3 H-F and 0.5 μM F in PBS-sucrose. 1 ml of substrate solution was added to each tube, and inhibitors were also added to each tube at a concentration of 10 μM, except for the “control” and “blank” tubes. 150 μL was added to all tubes except the blank, which corrected for the amount of 3 H-F formed simultaneously. The tube was incubated for 60 minutes at 37 ° C. in a mechanically shaking water bath. The amount of kidney, liver homogenate and incubation time used were obtained from enzyme-dependent and time-dependent assays. After incubation, 50 μL of recovery containing 5000 cpm / 50 μL of 14 C-E and 50 μg / 50 μL of unlabeled E was added to correct for losses that occurred in the next step (visualize spots on TLC plates) To do). The aqueous mixture was then extracted with 4 ml ether (2 × 30 sec cycle, vigorous mixing). After freezing the aqueous phase, the ether (upper) layer was decanted into a small tube and evaporated at 45 ° C. until completely dry. The residue was then redissolved in 6 drops of ether and transferred to a TLC plate. The TLC plate was developed with a chloroform: methanol (9: 1 v / v) solvent system, and the TLC plate was developed for about 90 minutes until the tip of the solvent moved about 18 cm. The position of product E was visualized under UV light, cut out from the TLC plate and placed in a scintillation vial. Radioactivity was eluted with 0.5 ml methanol over 5 minutes. 0.5 ml PBS-sucrose and 10 ml Ecoscint were then added, mixed vigorously and then counted in a scintillation counter. Two total active vials were prepared before counting the samples. These included 0.5 ml substrate solution, 50 μL harvest, 0.5 ml methanol and 10 ml Ecscint. These two all active vials were required to determine the amount of 14 C-E and 3 H-F initially added and perform the calculations.
酵素アッセイを、各実験について指定された181μM NADPH、1mM グルコース−6−リン酸およびコルチゾン濃度の存在下で行なった:
酵素アッセイ緩衝液:
1mM EDTAを含有する30mM Tris−HCl,pH 7.2
抗体結合緩衝液:
0.1M NaClおよび0.1%ゼラチンを含有する50mM Tris−HCl,pH 8。
Enzyme assays were performed in the presence of 181 μM NADPH, 1 mM glucose-6-phosphate and cortisone concentrations specified for each experiment:
Enzyme assay buffer:
30 mM Tris-HCl containing 1 mM EDTA, pH 7.2
Antibody binding buffer:
50 mM Tris-HCl, pH 8, containing 0.1 M NaCl and 0.1% gelatin.
基質の調製:
必要とされるアッセイ濃度(175μM)の600倍でエタノール中のコルチゾン溶液を調製する。アッセイ緩衝液中に50分の1で希釈する。
NADPHを、アッセイ緩衝液中1.8mg/mlの溶液として調製する。
G−6−Pを、アッセイ緩衝液中3.65mg/mlの溶液として調製する。
これらの3つの溶液を1:1:1で混合して、各サンプルへの25μlの添加に十分な量の溶液を作製する。25μlあたり0.5μCiに滴定したコルチゾンを添加し、溶液を十分に混合する。
Substrate preparation:
Prepare a cortisone solution in ethanol at 600 times the required assay concentration (175 μM). Dilute 1:50 in assay buffer.
NADPH is prepared as a 1.8 mg / ml solution in assay buffer.
G-6-P is prepared as a 3.65 mg / ml solution in assay buffer.
These three solutions are mixed 1: 1: 1 to make enough solution for the addition of 25 μl to each sample. Was added titrated cortisone to 0.5 mu Ci per 25 [mu] l, the solution is mixed thoroughly.
(ラジオイムノアッセイ)
11β−HSD1酵素アッセイを、各実験について所定のu底ポリプロピレン96ウェルプレートまたは1.5ml Eppendorfチューブ中にて、上記の標準的な操作手順に従って行なった。酵素反応を停止した後、他に示されない限り、緩衝液3中で調製した100μlの抗体を、試験サンプルに添加し、100μlの緩衝液3をNSBサンプルに添加した。サンプルを37℃にて1時間インキュベートし、氷上で15分間冷やした。緩衝液3中で所定の濃度に調製したデキストランでコーティングしたチャコール(50μl/サンプル)を加え、サンプルを混合し(チューブについてはボルテックスし、96ウェルプレートについては8チャネルピペットで5回吸引した)、さらに10分間冷ました。サンプルを4℃にて2000×gで15分間遠心分離し、炭を沈殿させた。上清のアリコート(100μl)をOptiplateに移し、150〜200μlのMicroscint 40中でTopcount上でカウントした。いくつかの実験において、上清のアリコートをシンチレーションバイアルに移し、5ml Ultima Goldシンチラント中、Ticarb LSC上でカウントした。
(Radioimmunoassay)
The 11β-HSD1 enzyme assay was performed according to the standard operating procedure described above in either u-bottom polypropylene 96 well plates or 1.5 ml Eppendorf tubes for each experiment. After stopping the enzymatic reaction, unless otherwise indicated, 100 μl of antibody prepared in buffer 3 was added to the test sample and 100 μl of buffer 3 was added to the NSB sample. Samples were incubated at 37 ° C. for 1 hour and chilled on ice for 15 minutes. Add dextran- coated charcoal (50 μl / sample) adjusted to the prescribed concentration in buffer 3 and mix the sample (vortex for tubes and aspirate 5 times for 8-well pipettes for 96-well plates) Cooled for another 10 minutes. The sample was centrifuged at 2000 × g for 15 minutes at 4 ° C. to precipitate charcoal. An aliquot (100 μl ) of the supernatant was transferred to an Optiplate and counted on a Topcount in 150-200 μl Microscint 40. In some experiments, aliquots of the supernatant were transferred to scintillation vials and counted on a Ticarb LSC in 5 ml Ultima Gold scintillant .
文献は、いくつかの水溶液からのコルチゾールの抽出法を詳述する[16,17]。使用方法を選択するために、[ 14 C]−標識したコルチゾールをNENから入手した。ストックを、50μl中の4000 DPMを含むリン酸緩衝化生理食塩水(PBS)中で、冷やしたコルチゾール(1μg)をキャリアとして添加して調製した。最終エタノール濃度は0.4%であった。この溶液のアリコートをガラス管(100μl)に添加し、以下の抽出を行なった:1. 1mlのCH2Cl2、ボルテックスし、相分離濾紙(Whatman,IPS)を通過させる、2.1mlの酢酸エチル、ボルテックスし、相分離濾紙を通す、3. 1mlのCH2Cl2および200μlの0.05% CaCl2、ボルテックスし、遠心分離(500gで5分間)し、そして、上側の水相を除去する、4. 1mlの酢酸エチルおよび200μlの0.05% CaCl2、ボルテックスし、遠心分離(500gで5分間)し、そして、上側の有機層を回収する。有機相を乾燥させ、残留物を100μlのIMS中に取った。このアリコートをTLCプレート上にスポットし、前としてプレートを展開させた。ローダミンBで可視化した後、スポットをシンチレーションバイアルにスクレープし、5mlのUlttimaゴールドシンチラント中、液体シンチレーションカウンター(Packard TriCarb)でカウントした。抽出効率を算出し、図4に示す。 The literature details the extraction of cortisol from several aqueous solutions [16, 17]. [ 14 C] -labeled cortisol was obtained from NEN to select the method of use. Stocks were prepared by adding chilled cortisol (1 μg) as a carrier in phosphate buffered saline (PBS) containing 4000 DPM in 50 μl. The final ethanol concentration was 0.4%. An aliquot of this solution was added to a glass tube (100 μl) and the following extractions were performed: 2. 1 ml CH 2 Cl 2 , vortexed and passed through phase separation filter paper (Whatman, IPS), 2.1 ml ethyl acetate, vortexed and passed through phase separation filter paper 3. Vortex 1 ml CH 2 Cl 2 and 200 μl 0.05% CaCl 2 , centrifuge (500 g for 5 min) and remove the upper aqueous phase. Vortex 1 ml ethyl acetate and 200 μl 0.05% CaCl 2 , centrifuge (500 g for 5 min) and collect upper organic layer. The organic phase was dried and the residue was taken up in 100 μl IMS. This aliquot was spotted on a TLC plate and the plate was developed as before. After visualization with rhodamine B, the spots were scraped into scintillation vials and counted in a liquid scintillation counter (Packard TriCarb) in 5 ml of Ultima Gold scintillant. The extraction efficiency is calculated and shown in FIG.
(ヒトおよびラットの肝臓ミクロソームの11β−HSD1活性)
ラットおよびヒト肝臓ミクロソームにおける11β−HSD1活性を評価して、酵素活性の測定に必要とされる最小限のミクロソームタンパク質濃度を決定した。実験を、Bradford法に従って行った[14]。これらのアッセイを、緩衝液2中で実施し、用いたコルチゾンの濃度は、インキュベーションあたり、0.5μCiの[3H]−コルチゾンを含有する2μMであった。ミクロソームを、インキュベーションあたり、100μlの最終インキュベーション容量にて、ガラス管内で50μg〜400μgの範囲の濃度にて試験した。サンプルを1時間37℃の振盪水浴中にてインキュベートし、1mlの酢酸エチルを添加してアッセイを停止した。回収物を回収するために、50μlの[14C]−コルチゾールをサンプルに添加し、その後、200μlの0.05% CaCl2を添加した。サンプルを激しく混合し、上記のように遠心分離した。上側の有機相を除去し、乾燥させ、残留物を100μlのメタノールに溶解し、そして50μlのアリコートをTLCプレート上にスポットさせた。これを、上記のように展開させた。サンプルを二重標識プログラムを用いてTriCarb液体シンチレーションカウンター上でカウントした。回収効率を、50μlの[14C]−コルチゾール溶液中に得たDPMから決定し、これを、サンプルを用いてカウントした。結果を図5に示す。
(11β-HSD1 activity of human and rat liver microsomes)
11β-HSD1 activity in rat and human liver microsomes was evaluated to determine the minimum microsomal protein concentration required to measure enzyme activity. Experiments were performed according to the Bradford method [14]. These assays were performed in buffer 2 and the concentration of cortisone used was 2 μM containing 0.5 μCi [ 3 H] -cortisone per incubation. Microsomes were tested at concentrations ranging from 50 μg to 400 μg in glass tubes at a final incubation volume of 100 μl per incubation. Samples were incubated for 1 hour in a 37 ° C. shaking water bath and 1 ml of ethyl acetate was added to stop the assay. To recover the collected substance, [14 C] of 50 [mu] l - added cortisol in the sample, followed by addition of 0.05% CaCl 2 in 200 [mu] l. Samples were mixed vigorously and centrifuged as above. The upper organic phase was removed, dried, the residue was dissolved in 100 μl methanol , and a 50 μl aliquot was spotted on a TLC plate. This was developed as described above. Samples were counted on a TriCarb liquid scintillation counter using a double labeling program. Recovery efficiency was determined from DPM obtained in 50 μl of [ 14 C] -cortisol solution, which was counted with the sample. The results are shown in FIG.
ラットおよびヒトのミクロソームにおける11β−HSD1活性は類似しており、ラットおよびヒトのミクロソームについて、それぞれ、0.7pmol/mg/分および0.5pmol/mg/分であった。ヒトミクロソームにおける活性は、ミクロソームタンパク質濃度とは無関係であるようで、このことは、抽出されたタンパク質濃度範囲が高すぎることを示唆し得る。 11β-HSD1 activity in rat and human microsomes was similar, with 0.7 and 0.5 pmol / mg / min for rat and human microsomes, respectively. Activity in human microsomes appears to be independent of microsomal protein concentration, which may suggest that the extracted protein concentration range is too high.
活性に対する基質濃度の影響を試験した。[3H]−コルチゾン濃度を0.5μCi/サンプルに一定に保ち、未標識のコルチゾンを、44nMから2μMまで変化させた。アッセイを、37℃にて、サンプルあたり10μgのミクロソームタンパク質、30分のインキュベーション時間で実施した。結果を図8に示す。これらのデータの二重逆数プロット(Lineweaver−Burke)は、660nMのコルチゾンについての見かけのKmを与える、図9。 The effect of substrate concentration on activity was tested. [ 3 H] -cortisone concentration was kept constant at 0.5 μCi / sample, and unlabeled cortisone was varied from 44 nM to 2 μM. The assay was performed at 37 ° C. with 10 μg microsomal protein per sample, 30 min incubation time. The results are shown in FIG. These data double reciprocal plot (Lineweaver-Burke) gives the Km apparent for cortisone 660 n M, FIG.
グリシレチン酸およびカルベノキソロンは、それぞれ、40nMおよび119nMのIC50値を生じる。SPA形式および組換え11β−HSDを用いてBarfらによって、カルベノキソロンについて報告されたIC50は、330nMであり[15]、およそ3倍強力でない。この2つのアッセイ系における能力の差は、おそらく、異なるアッセイ条件(tlc終点と比較したSPA、また、酵素供給源:組換え酵素に対して天然の肝臓酵素)によるものである。 Glycyretic acid and carbenoxolone yield IC 50 values of 40 nM and 119 nM, respectively. The IC 50 reported for carbenoxolone by Barf et al. Using the SPA format and recombinant 11β-HSD is 330 nM [15], which is approximately 3 times less potent. The difference in capacity between the two assay systems is probably due to different assay conditions (SPA compared to the tlc endpoint and also the enzyme source: natural liver enzyme versus recombinant enzyme).
このアッセイは、予測されていた通りに、標準曲線(313pg/ml〜10,000pg/ml)においてコルチゾールを検出したが、酵素アッセイサンプルから得られたシグナルは、ミクロソームタンパク質濃度の増加と共に減少し、このことは、ミクロソームタンパク質がイムノアッセイに影響し得ることを示唆する、図12(A)。外因性コルチゾンの添加が、酵素アッセイサンプルにおいて検出されたコルチゾールのレベルに影響を有さず、これは、抗体が、コルチゾンと交差反応しないことを示唆する、図12(B)。酵素アッセイ緩衝液中に界面活性剤を含めても、影響はほとんどなかった、図12(C)。 This assay detected cortisol in the standard curve ( 313 pg / ml-10,000 pg / ml ), as expected, but the signal obtained from the enzyme assay sample decreased with increasing microsomal protein concentration, This suggests that microsomal proteins can affect immunoassays (FIG. 12 (A)). The addition of exogenous cortisone has no effect on the level of cortisol detected in the enzyme assay sample, suggesting that the antibody does not cross-react with cortisone (FIG. 12 (B)). Inclusion of a surfactant in the enzyme assay buffer had little effect, FIG. 12 (C).
11β−HSD1活性を検出するためのイムノアッセイ系を用いることが実行可能であるかを決定するために、このアッセイ条件を変更した;サンプルあたり24μgのミクロソームタンパク質および緩衝液2中、2μMのコルチゾン基質。酵素活性をまた、サンプル内に存在する場合、ステロイド置換試薬(コルチゾール結合タンパク質からコルチゾールを放出するキット成分)の添加後にサンプル中で測定した。アッセイは、標準曲線(313pg/ml〜10,000pg/ml)内のコルチゾールを検出した。図13は、異なる群について得られた、406nmにおける吸光度を示す。 The assay conditions were changed to determine if it was feasible to use an immunoassay system to detect 11β-HSD1 activity; 2 μM cortisone substrate in 24 μg microsomal protein and buffer 2 per sample. Enzyme activity was also measured in the sample after addition of a steroid displacement reagent (kit component that releases cortisol from the cortisol-binding protein) if present in the sample. The assay detected cortisol within a standard curve ( 313 pg / ml to 10,000 pg / ml ). FIG. 13 shows the absorbance at 406 nm obtained for the different groups.
コルチゾール標準の最低濃度および最高濃度は、図13において、313pg/mlおよび10,000pg/mlであると示され、NSB吸光度は、このアッセイにおいて得られるダイナミックレンジを示す。 The minimum and maximum concentrations of the cortisol standard are shown in FIG. 13 as 313 pg / ml and 10,000 pg / ml , and NSB absorbance indicates the dynamic range obtained in this assay.
ミクロソームタンパク質と共にインキュベートしたサンプルから取った反応混合物の存在下で得られた吸光度(「酵素」)は、ミクロソームタンパク質を含まない反応混合物の存在下で得られた吸光度(「酵素なし」)よりも低く、コルチゾールのレベルの増加を示す。 The absorbance (“enzyme”) obtained in the presence of the reaction mixture taken from the sample incubated with the microsomal protein is lower than the absorbance obtained in the presence of the reaction mixture without the microsomal protein (“no enzyme”). , Showing increased levels of cortisol.
0.67μg/ウェル〜6.7μg/ウェルの濃度における抗体力価を試験した。11β−HSD1アッセイを、20μg/ウェルのヒトミクロソームタンパク質を用いて実施し、最適なシグナルバックグラウンド比を生じた。各抗体濃度を、「酵素なし」ブランク(ミクロソームから構成される緩衝液)、「GAブランク」(ミクロソームの前に10μlの停止溶液を添加した)およびコントロール群に対して試験した。結果を図16および17に示す。 Antibody titers at concentrations from 0.67 μg / well to 6.7 μg / well were tested. The 11β- HSD1 assay was performed with 20 μg / well of human microsomal protein, producing an optimal signal background ratio. Each antibody concentration was tested against a “no enzyme” blank (buffer composed of microsomes), a “GA blank” (10 μl stop solution added before microsomes) and a control group. The results are shown in FIGS.
RIA検出を用いて、ヒト肝臓ミクロソームタンパク質濃度との酵素活性の直線性を試験する。11β−HSD1アッセイを、ミクロソームタンパク質濃度を1μg/ウェルから40μg/ウェルに変化させて実施した。11β−HSD1活性は、20μg/ウェルまではタンパク質と直線性であり(図18)、従来の酵素アッセイで得られた結果(図7)
を確認した。
RIA detection is used to test the linearity of enzyme activity with human liver microsomal protein concentrations. The 11β- HSD1 assay was performed with the microsomal protein concentration changed from 1 μg / well to 40 μg / well. 11β- HSD1 activity is linear with protein up to 20 μg / well (FIG. 18) and results obtained with conventional enzyme assays (FIG. 7)
It was confirmed.
酵素アッセイおよびRIAステージの両方が、同じ緩衝液中で行なわれ、両方の相が、酵素アッセイ緩衝液(緩衝液2)中または緩衝液3(RIA緩衝液)中のいずれかで行なわれるように、プロトコールを単純化する。用いたミクロソームタンパク質濃度は、10μg/ウェルであり、コルチゾン濃度は、175nMであった。酵素アッセイおよびRIAの両方を緩衝液3中で実施すると、データがわずかに改善するようである、図20。 Both enzyme assay and RIA stage are performed in the same buffer, and both phases are performed either in enzyme assay buffer (buffer 2) or buffer 3 (RIA buffer). Simplify the protocol. The microsomal protein concentration used was 10 μg / well and the cortisone concentration was 175 nM . When both the enzyme assay and RIA are performed in buffer 3, the data appears to improve slightly, FIG.
10μg/ウェルのミクロソームタンパク質および175nMの基質を用いると、反応は、30分までの時点では直線性である。これらの結果は、175nMの基質濃度が、低すぎることを示す。従来の11β−HSD1アッセイにおいて観察された見かけのKmは、660nMであった(図8および9)が、これらのアッセイは、終点での測定値であり、従って、最初の速度が、30分間のインキュベーション時間で、低基質群において測定されたかどうかは定かではない。しかし、ヒト肝臓ミクロソーム11β−HSD1アッセイにおけるコルチゾンについて公開されているKm値は、μmol濃度の範囲内である[18,19]。175nMの基質は、見かけのKmより十分に低いが、以下の2つの理由から、濃度を有意に増加する可能性はない:
(i)化合物がコルチゾンと競合する場合、測定される阻害は、基質が参考文献1において用いられた濃度を上回って増える場合に落ちる
(ii)基質濃度を増加することが、標識の特異的活性を減少し、アッセイの感度を低下させる。このことは、より高い濃度の[3H]−コルチゾンを添加することによって克服され得るが、このプロトコールは0.5μCi/ウェルを用い、より高いレベルの放射活性が用いられる場合に、コストの影響が存在する。
With 10 μg / well microsomal protein and 175 nM substrate, the reaction is linear up to 30 minutes. These results indicate that the substrate concentration of 175 nM is too low. The apparent Km observed in the conventional 11β-HSD1 assay was 660 nM (FIGS. 8 and 9), but these assays were endpoint measurements, so the initial rate was 30 min. It is not clear whether the incubation time was measured in the low substrate group. However, published Km values for cortisone in the human liver microsome 11β-HSD1 assay are in the μmol concentration range [18, 19]. The 175 nM substrate is well below the apparent Km, but there is no possibility of significantly increasing the concentration for two reasons:
(I) When the compound competes with cortisone, the measured inhibition falls when the substrate increases above the concentration used in ref. 1 (ii) Increasing the substrate concentration increases the specific activity of the label Decrease the sensitivity of the assay. This can be overcome by adding higher concentrations of [ 3 H] -cortisone, but this protocol uses 0.5 μCi / well and the cost impact when higher levels of radioactivity are used. Exists.
図23中に示されるこれらのデータのLineweaver−Burkeプロットから決定した見かけのKm(700nM)は、tlc形式の11β−HSD1アッセイ(図9、見かけのKm 約660nM)において決定したものと非常に類似する。これらのデータは、10μgのミクロソームタンパク質では、酵素が、30分のインキュベーションの時間にわたって、175nMのコルチゾンにおいても飽和していないことを示唆する。 The apparent Km (700 nM) determined from the Lineweaver-Burke plot of these data shown in FIG. 23 is very similar to that determined in the tlc- format 11β-HSD1 assay (FIG. 9, apparent Km approximately 660 nM). To do. These data suggest that at 10 μg of microsomal protein, the enzyme is not saturated even at 175 nM cortisone over a 30 minute incubation period.
グリシレチン酸は、41nMのIC50で酵素の濃度関連阻害を生じ、良好なフィット値(r 2 =0.962)およびヒルスロープ(Hillslope)を有する。これは、tlc形式アッセイを用いて生じた40nMの値に類似する(図10を参照のこと)。30nMのIC50値は、基質としてデヒドロ−デキサメタゾンを用いて、ヒト肝臓ミクロソームにおける11β−HSD1のグリシレチン酸阻害について報告されている[19]。しかし、これらの値は、Barfらにより報告された値よりも低い[15]。 Glycyretic acid produces a concentration-related inhibition of the enzyme with an IC 50 of 41 nM and has a good fit value ( r 2 = 0.962) and Hillslope. This is similar to the 40 nM value generated using the tlc format assay (see FIG. 10). An IC 50 value of 30 nM has been reported for glycyrrhetinic acid inhibition of 11β-HSD1 in human liver microsomes using dehydro-dexamethasone as a substrate [19]. However, these values are lower than those reported by Barf et al. [15].
DGS03130B(STX701)
淡黄色結晶DGS03130A(45mg;14%)。mp169 C;TLC Rf:0.42 CH2Cl2/EtOAc(4:1);
DGS03130B (STX701)
Pale yellow crystalline DGS03130A (45 mg; 14%). mp 169 C; TLC R f : 0.42 CH 2 Cl 2 / EtOAc (4: 1);
(2−[6−(3−クロロ−2−メチルベンゼンスルホニルアミノ)−ベンゾチアゾール−2−イルスルファニル]−N,N−ジエチルアセトアミド(STX755,XDS01145)および2−[6−(3−クロロ−2−メチルベンゼンスルホニルアミノ)−ベンゾチアゾール−2−イル]−N,N−ジエチルアセトアミド(STX763,XDS01145B))
DMC(5ml)中のAlCl3(50mg)の懸濁液に、ジエチルアミン(0.4ml)を添加した。溶液を窒素下、室温にて10分間撹拌した。[6−(3−クロロ−2−メチルベンゼンスルホニルアミノ)−ベンゾチアゾール−2−イルスルファニル]−酢酸エチルエステル(STX752,100mg)を添加し、混合物を室温にて30分間撹拌し続けた。反応を水でクエンチし、DCMと5% NaHCO3との間で分配した。有機層を水で洗浄し、MgSO4で乾燥させ、真空下でエバポレートして、黄色の残留物を生じ、これを、溶離溶媒として20〜30% 酢酸エチル−DCMを用いるフラッシュカラムクロマトグラフィーにより精製した。STX755(50mg,47%)を白色固体として得た。TLC Rf 0.60の単一スポット(25% EtOAc/DCM);HPLC純度 89%(tR 10% 水−メタノール中2.7分);
(2- [6- (3-Chloro-2-methylbenzenesulfonylamino) -benzothiazol-2-ylsulfanyl] -N, N-diethylacetamide (STX755, XDS01145) and 2- [6- (3-chloro- 2-methylbenzenesulfonylamino) -benzothiazol-2-yl] -N, N-diethylacetamide (STX763, XDS01145B))
To a suspension of AlCl 3 (50 mg) in DMC (5 ml) was added diethylamine (0.4 ml). The solution was stirred at room temperature for 10 minutes under nitrogen. [6- (3-Chloro-2-methylbenzenesulfonylamino) -benzothiazol-2-ylsulfanyl] -acetic acid ethyl ester (STX752,100 mg) was added and the mixture continued to stir at room temperature for 30 minutes. The reaction was quenched with water and partitioned between DCM and 5% NaHCO 3 . The organic layer is washed with water, dried over MgSO 4 and evaporated under vacuum to give a yellow residue which is purified by flash column chromatography using 20-30% ethyl acetate-DCM as the eluting solvent. did. STX755 (50 mg, 47%) was obtained as a white solid. TLC R f 0.60 single spot (25% EtOAc / DCM); HPLC purity 89% (t R 10% water-2.7 min in methanol);
アセトン(3mL)中のSTX753(66mg、0.19mmol)の溶液に、炭酸カリウム(66mg)を添加し、その後、ヨウ化メチル(66mg)を添加した。混合物を室温にて2時間撹拌し、DCM中に抽出し、ブラインで洗浄した。硫酸ナトリウムで乾燥させた後、溶媒を真空下で除去して、油状の残留物を得、これを、フラッシュクロマトグラフィーにより精製した。オフホワイトの固体(59mg、80%)を得た。TLC Rf 0.37の単一スポット(100% DCM);HPLC純度 99%(tR 10% 水−メタノール中2.0分);1H NMR(400MHz,
To a solution of STX753 (66 mg, 0.19 mmol) in acetone (3 mL) was added potassium carbonate (66 mg) followed by methyl iodide (66 mg). The mixture was stirred at room temperature for 2 hours, extracted into DCM and washed with brine. After drying over sodium sulfate, the solvent was removed in vacuo to give an oily residue that was purified by flash chromatography. An off-white solid (59 mg, 80%) was obtained . TLC R f 0.37 single spot (100% DCM); HPLC purity 99% (2.0% in t R 10% water-methanol); 1 H NMR (400 MHz,
オフホワイトの結晶固体。TLC Rf 0.49の単一スポット(10% EtOAc/DCM);HPLC純度 98%(tR 20% 水−メタノール中2.0分);
Off-white crystalline solid. TLC R f 0.49 single spot (10% EtOAc / DCM); HPLC purity 98% (t R 20% water-2.0 min in methanol);
白色結晶固体。TLC Rf 0.76の単一スポット(10% EtOAc/DCM);HPLC純度>99%(tR 10% 水−メタノール中2.9分);
White crystalline solid. TLC R f 0.76 single spot (10% EtOAc / DCM); HPLC purity> 99% (t R 10% water-2.9 min in methanol);
オフホワイトのシロップ。TLC Rf 0.78の単一スポット(10% EtOAc/DCM);HPLC純度 85%(tR 10% 水−メタノール中4.2分);
Off-white syrup. TLC R f 0.78 single spot (10% EtOAc / DCM); HPLC purity 85% (t R 10% water-4.2 min in methanol);
DCM中のアリールスルホニルクロリド(1.1当量)の溶液に、ピリジン(2.2当量)および触媒量のDMAPを添加し、その後、対応するアミン(1当量)を添加した。反応混合物を窒素下、室温にて、4〜16時間撹拌し、TLCが反応の完了を示した後、次いで、酢酸エチルと5%炭酸水素ナトリウムとの間で分配した。有機層をブラインで洗浄し、硫酸ナトリウムで乾燥させ、真空下で濃縮して、固体または粘性シロップとして粗生成物を生じた。次いで、化合物をフラッシュクロマトグラフィー(メタノール−DCM勾配溶出)により精製して、結晶固体として所望のアリールスルホンアミドを生じた。収率は、50〜80%の範囲である。
To a solution of arylsulfonyl chloride (1.1 eq) in DCM was added pyridine (2.2 eq) and a catalytic amount of DMAP followed by the corresponding amine (1 eq). The reaction mixture was stirred at room temperature under nitrogen for 4-16 hours and then partitioned between ethyl acetate and 5% sodium bicarbonate after TLC showed the reaction was complete. The organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum to give the crude product as a solid or viscous syrup. The compound was then purified by flash chromatography (methanol-DCM gradient elution) to yield the desired arylsulfonamide as a crystalline solid. The yield is in the range of 50-80%.
3−クロロ−N−(1,2−ジメチル−1H−ベンゾイミダゾール−6−イル)−2−メチルベンゼンスルホンアミド(STX975,XDS02001)
白色結晶固体。Mp265−266 C;TLC Rf 0.43の単一スポット(5% メタノール/DCM);HPLC純度>99%(tR 10% 水−メタノール中2.分);
3-Chloro-N- ( 1,2-dimethyl-1H-benzimidazol-6-yl) -2-methylbenzenesulfonamide (STX975, XDS02001)
White crystalline solid. Mp265-266 C; single spot of TLC R f 0.43 (5% methanol / DCM); HPLC purity> 99% (t R 10% water-2.min in methanol);
白色結晶固体。Mp 283−283℃。TLC R f 0.38の単一スポット(5% メタノール/DCM);HPLC純度>99%(tR 10% 水−メタノール中2.0分);
White crystalline solid. Mp 283-283 ° C. TLC R f 0.38 single spot (5% methanol / DCM); HPLC purity> 99% (t R 10% water-2.0 min in methanol);
N−(2−メチル−1−フェニル−1H−ベンズイミダゾール−5−イル)−アセトアミド:
N’−フェニル−ベンゼン−1,2,4−トリアミン(800mg,4mmol)を、酢酸(10mML)中に溶解させ、無水酢酸(1.0mL)をこの溶液に添加した。混合物を80℃にて6時間撹拌し、室温まで冷却して、5%炭酸ナトリウムで中和し、次いで、酢酸エチルで抽出した。有機相をブラインで洗浄し、硫酸マグネシウムで乾燥させ、濃縮して残留物を生じ、これをエタノールから結晶化した。褐色の結晶固体(0.85g,80%)を得た。Mp 231〜232℃;TLC Rf 0.39の単一スポット(10% メタノール/DCM);
N- (2-Methyl-1-phenyl-1H-benzimidazol-5-yl) -acetamide:
N′-phenyl-benzene-1,2,4-triamine (800 mg, 4 mmol) was dissolved in acetic acid (10 mM L) and acetic anhydride (1.0 mL) was added to this solution. The mixture was stirred at 80 ° C. for 6 hours, cooled to room temperature, neutralized with 5% sodium carbonate, and then extracted with ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and concentrated to give a residue that was crystallized from ethanol. A brown crystalline solid (0.85 g, 80%) was obtained. Mp 231-232 ° C; TLC R f 0.39 single spot (10% methanol / DCM);
本発明は、例としてのみ添付の図面を参照することによって、さらに詳細に記載される。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0224830.0A GB0224830D0 (en) | 2002-10-24 | 2002-10-24 | Compound |
US43663502P | 2002-12-30 | 2002-12-30 | |
PCT/GB2003/004590 WO2004037251A1 (en) | 2002-10-24 | 2003-10-23 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006514614A JP2006514614A (en) | 2006-05-11 |
JP2006514614A5 true JP2006514614A5 (en) | 2006-10-12 |
Family
ID=32178879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004546183A Pending JP2006514614A (en) | 2002-10-24 | 2003-10-23 | 11β-hydroxysteroid dehydrogenase type 1 and type 2 inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1556040A1 (en) |
JP (1) | JP2006514614A (en) |
KR (1) | KR20050059294A (en) |
AU (1) | AU2003274373A1 (en) |
BR (1) | BR0315605A (en) |
CA (1) | CA2501228A1 (en) |
MX (1) | MXPA05004434A (en) |
NO (1) | NO20052469L (en) |
PL (1) | PL376301A1 (en) |
WO (1) | WO2004037251A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302572D0 (en) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302570D0 (en) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
GB0408771D0 (en) * | 2004-04-20 | 2004-05-26 | Sterix Ltd | Compound |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
DE102004047272A1 (en) * | 2004-09-24 | 2006-04-06 | Schering Ag | Inhibitors of soluble adenylate cyclase |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
NZ555966A (en) | 2005-01-05 | 2011-03-31 | Abbott Lab | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
CN101142172A (en) | 2005-01-05 | 2008-03-12 | 艾博特公司 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
WO2006097337A2 (en) * | 2005-03-18 | 2006-09-21 | Onepharm Gmbh | 11β-HYDROXYSTEROID DEHYDROGENASES |
EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
EP1891063B1 (en) * | 2005-05-10 | 2012-07-25 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
EP2322506A1 (en) | 2005-07-01 | 2011-05-18 | Eli Lilly and Company | Histamine H3 receptor agents, preparation and therapeutic uses |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
US7825122B2 (en) | 2005-12-14 | 2010-11-02 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
WO2008017381A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
DE102007012284A1 (en) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
JP5736098B2 (en) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | Pharmaceutical composition for treating central nervous system disorders |
DE102008019838A1 (en) * | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | New arylsulfonylglycine derivatives, their preparation and their use as pharmaceuticals |
AR072707A1 (en) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM |
US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
JP5574431B2 (en) | 2008-08-29 | 2014-08-20 | 興和株式会社 | 1-adamantyl azetidin-2-one derivative and pharmaceutical containing the same |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP5477973B2 (en) | 2008-10-29 | 2014-04-23 | 興和株式会社 | 1,2-diazetidin-3-one derivative and medicament containing the same |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
ES2619557T3 (en) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | PKM2 activators for use in cancer treatment |
DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
EP3241554B1 (en) | 2009-06-29 | 2020-01-29 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives having an anticancer activity |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8829026B2 (en) | 2010-10-01 | 2014-09-09 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
EP2655350B1 (en) | 2010-12-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
PE20140859A1 (en) | 2011-02-25 | 2014-07-25 | Merck Sharp & Dohme | NOVELTY DERIVATIVES OF CYCLIC AZABENZIMIDAZOLE USEFUL AS ANTIDIABETIC AGENTS |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120050A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012151451A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9181231B2 (en) | 2011-05-03 | 2015-11-10 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112015002080A2 (en) | 2012-08-02 | 2017-07-04 | Merck Sharp & Dohme | compound, pharmaceutical composition, use of a compound, and method of treating or preventing a disorder, condition or disease |
CN112552364A (en) * | 2013-01-23 | 2021-03-26 | 司菲埃拉制药私人有限公司 | Novel 11 beta-hydroxysteroid compounds for use in mitochondrial biogenesis and diseases associated with mitochondrial dysfunction or depletion |
EP2958562A4 (en) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Antidiabetic bicyclic compounds |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN106714770B (en) | 2014-07-23 | 2024-04-19 | 斯法尔制药私人有限公司 | Hydroxysteroid compound, intermediate, preparation method, composition and application thereof |
MA44392B1 (en) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | METHODS OF USING PYRUVATE KINASE ACTIVATORS |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
EP3676255A1 (en) | 2017-08-29 | 2020-07-08 | Rutgers, The State University University Of New Jersey | Therapeutic indazoles |
WO2020120576A1 (en) * | 2018-12-11 | 2020-06-18 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | p38α AUTOPHOSPHORYLATION INHIBITORS |
KR102433502B1 (en) * | 2020-01-17 | 2022-08-18 | 재단법인 대구경북첨단의료산업진흥재단 | Novel compound, preparation method thereof, and use thereof |
WO2023236920A1 (en) * | 2022-06-07 | 2023-12-14 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
JPS62207271A (en) * | 1986-03-06 | 1987-09-11 | Yamanouchi Pharmaceut Co Ltd | Condensed ring compound substituted with 2-pyridylmethylthio group or 2-pyridylmethylsulfinyl group |
JPS6355543A (en) * | 1986-08-26 | 1988-03-10 | Konica Corp | Silver halide photographic sensitive material preventing sweating phenomenon and formation of static mark |
KR100225087B1 (en) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | The expression of phytase in plants |
GB9020338D0 (en) * | 1990-09-18 | 1990-10-31 | Lilly Industries Ltd | Pharmaceutical compounds |
EP1586558A3 (en) * | 1995-01-20 | 2005-10-26 | G.D. Searle LLC. | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors |
TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
JP2002527419A (en) * | 1998-10-08 | 2002-08-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Pyrrole-2,5-diones as GSK-3 inhibitors |
SE0001899D0 (en) * | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
KR100526091B1 (en) * | 2000-10-06 | 2005-11-08 | 다나베 세이야꾸 가부시키가이샤 | Aliphatic Nitrogenous Five-Membered Ring Compounds |
JP5145624B2 (en) * | 2000-12-22 | 2013-02-20 | コニカミノルタホールディングス株式会社 | Silanol group-containing recording medium ink, polymer particle aqueous dispersion, and inkjet recording water-based ink |
-
2003
- 2003-10-23 AU AU2003274373A patent/AU2003274373A1/en not_active Abandoned
- 2003-10-23 EP EP03758357A patent/EP1556040A1/en not_active Withdrawn
- 2003-10-23 WO PCT/GB2003/004590 patent/WO2004037251A1/en active Application Filing
- 2003-10-23 CA CA002501228A patent/CA2501228A1/en not_active Abandoned
- 2003-10-23 BR BR0315605-2A patent/BR0315605A/en not_active IP Right Cessation
- 2003-10-23 JP JP2004546183A patent/JP2006514614A/en active Pending
- 2003-10-23 MX MXPA05004434A patent/MXPA05004434A/en unknown
- 2003-10-23 PL PL03376301A patent/PL376301A1/en not_active Application Discontinuation
- 2003-10-23 KR KR1020057007048A patent/KR20050059294A/en not_active Application Discontinuation
-
2005
- 2005-05-23 NO NO20052469A patent/NO20052469L/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006514614A5 (en) | ||
EP0931060B1 (en) | Substituted n- (aminoiminomethyl or aminomethyl)phenyl propyl amides | |
US6300364B1 (en) | Medicinal compositions with cholesterol-lowering effect | |
US20060116419A1 (en) | Nf-kb inhibitors | |
EP3348557B1 (en) | Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout | |
EP0112623A2 (en) | 3-Aryl-5-pyrazole-carboxylic-acid derivatives, their preparation and pharmaceutical compositions | |
JP7092742B2 (en) | Pyrimidinone derivatives and their use to neutralize the biological activity of chemokines | |
RU2282627C2 (en) | Coumarone derivatives eliciting comt-inhibiting activity | |
JP2020519651A (en) | LXR modulator containing amine or (thio)amide | |
EP2098226A1 (en) | AKAP-PKA interaction inhibitors for use in the treatment of heart diseases | |
KR20180003545A (en) | Fused bicyclic compounds for the treatment of diseases | |
JP2514163B2 (en) | Pharmaceutical composition for treating asthma or inflammatory airway disease, which comprises a pyrimidone derivative and a similar compound | |
JP2009504692A (en) | Novel 4-amino-thieno [3,2-c] pyridine-7-carboxylic acid amide | |
US6255298B1 (en) | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases | |
ES2309567T3 (en) | DERIVATIVES OF IMIDAZOPIRIDINS AS INHIBITORS OF INDUCIBLE NON-SYNTHEASE. | |
CN110903224A (en) | Aryl sulfonamide compound, preparation method thereof, pharmaceutical composition and application | |
US11352331B2 (en) | Crystal and salt of 4-(naphthalen-1-yl)-4H-1,2,4-triazole compound and preparation method therefor | |
US7355055B2 (en) | Compounds for treatment of lipase-mediated diseases | |
US10822333B2 (en) | Pyridopyrimidines derivatives compounds | |
EP1937622A1 (en) | Compounds for treatment of lipase-mediated diseases | |
KR20200092971A (en) | Peroxisome proliferator responsive receptor activator | |
US4608381A (en) | Antiinflammatory 2-(trifluoroethylsulfonyl)benzimidazoles | |
JPS59104378A (en) | Carbostyril derivative | |
WO1997032847A1 (en) | Pyrrolidone derivatives | |
JPH09505081A (en) | Isoxazoline compounds as 5-lipoxygenase inhibitors |